What is the function of Quinine hydrochloride CAS 130-95-0?

Quinine hydrochloride CAS 130-95-0 is a chemical that inhibits or kills diseases such as benign vivax malaria, Plasmodium vivax and Plasmodium falciparum. If you want to know more about Quinine hydrochloride CAS 130-95-0, please read the following words.

• What is the pharmacodynamics of Quinine hydrochloride CAS 130-95-0?

• What is the pharmacokinetics of Quinine hydrochloride CAS 130-95-0?

• Who can't use Quinine hydrochloride CAS 130-95-0?

What is the pharmacodynamics of Quinine hydrochloride CAS 130-95-0?

Quinine hydrochloride CAS 130-95-0 is a quinoline derivative, which can combine with the DNA of Plasmodium to form a complex, inhibit the replication of DNA and the transcription of RNA, thereby inhibiting the protein synthesis of protozoa, and its effect is weaker than that of chloroquine. In addition, Quinine hydrochloride CAS 130-95-0 can reduce the oxygen consumption of Plasmodium, inhibit the phosphorylase in Plasmodium and interfere with its sugar metabolism. Quinine hydrochloride CAS 130-95-0 also caused malaria pigment agglutination, but it developed slowly, rarely formed large clumps, and was often accompanied by cell death. Electron microscope observation showed that the nucleus and outer membrane of the protozoa were swollen and had small vacuoles, and blood cell granules aggregated in the small vacuoles, which was different from the pigment agglutination of chloroquine. In blood, certain concentrations of quinine can cause premature rupture of parasitized red blood cells, thereby preventing schizont maturation. This product is ineffective for the infrared stage and cannot cure benign malaria. Long-term treatment can cure malignant disease, but it has no direct effect on the gametophyte of Plasmodium falciparum, so it cannot interrupt the transmission. Quinine hydrochloride CAS 130-95-0 has an inhibitory effect on the heart, prolongs the refractory period, slows conduction, and weakens its contractility. This product has a weak excitatory effect on the pregnant uterus.

What is the pharmacokinetics of Quinine hydrochloride CAS 130-95-0?

Quinine hydrochloride CAS 130-95-0 is rapidly and completely absorbed after oral administration. The protein binding rate is about 70%. After absorption, it is distributed in the whole body tissues, with the highest concentration in liver, followed by lung, kidney and spleen, and the least in skeletal muscle and nerve tissue. The peak plasma concentration occurs 1 to 3 hours after a single dose, and the T1/2 is 8.5 hours. Quinine is oxidized and decomposed in the liver and becomes ineffective rapidly. Its metabolites and a small amount of the original drug (about 10%) are all excreted by the kidneys. They appear in the urine 15 minutes after taking the drug, and almost all of them are excreted after 24 hours. Therefore, quinine has no effect. Accumulation.

Who can't use Quinine hydrochloride CAS 130-95-0?

Pregnant women are prohibited. Quinine hydrochloride CAS 130-95-0 has the effect of oxytocin. This product can pass through the placenta and cause fetal hearing damage and congenital defects of the central nervous system and limbs. Use with caution in lactating women.

Quinine hydrochloride CAS 130-95-0 should be used with caution in patients with asthma, atrial fibrillation and other serious heart diseases, glucose-6-phosphate dehydrogenase deficiency, myasthenia gravis, and optic neuritis.

Mulei (Wuhan) New Material Technology Co. Ltd’s skilled staff is easily accessible and collaborates with every aspect of our organization to better serve customers. their staff can provide the highest level of hydrochloride.